Mukul Agrawal is a distinguished investor and the founder of Param Capital Group, recognized for his strategic approach to investments in the Indian stock market. With over two decades of experience, he has built a reputation for identifying value opportunities and fostering innovation within the startup ecosystem.
As per the latest corporate shareholdings filed, Mukul Agrawal publicly holds 56 stocks with a net worth of over Rs. 6,739.0 Cr.
Here are the Mukul Agrawal stocks in which FII increased their stake up to 3.37% in Q2FY25 from Q1FY25;
Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Limited is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its formulation products include Divatrone, Maintane 500 injection, Maintane 250 injection, Maintane Tablet, and others.
With a market capitalization of Rs 1,413 crore, on Thursday, the shares were closed at Rs 534 per share, an increase of around 0.28 percent as compared to the previous closing price.
Ace investor Mukul Agrawal holds 463,023 equity shares equivalent to 1.8 percent in the company as of September 2024.
The foreign institutional investors of the company increased their stake by 1.20%, from 1.10% in Q1FY25 to 2.30% in Q2FY25. Additionally, 29.63% is owned by retail investors, 0.11% is held by domestic institutional investors, and 67.98% is owned by promoters.
Stanley Lifestyles Ltd
Stanley Lifestyles, which started its operations in 2007, is a luxury furniture brand in India. It is one of the few homegrown brands that operate at scale in both manufacturing and retail in the super-premium and luxury segments. The company sells its furniture products under the “Stanley” brand.
With a market capitalization of Rs 2,533 crore, on Thursday, the shares were closed at Rs 444 per share, an increase of around 1.73 percent as compared to the previous closing price.
Ace investor Mukul Agrawal holds 900,000 equity shares equivalent to 1.6 percent in the company as of September 2024.
The foreign institutional investors of the company increased their stake by 2.44%, from 2.62% in Q1FY25 to 5.06% in Q2FY25. Additionally, 17.26% is owned by retail investors, 20.86% is held by domestic institutional investors, and 56.81% is owned by promoters
Strides Pharma Science Ltd
Strides Pharma Science Limited is focused on the development and manufacture of IP-led niche and pharmaceutical products. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others.
With a market capitalization of Rs 13,015 crore, on Thursday, the shares were closed at Rs 1,415 per share, an increase of around 2 percent as compared to the previous closing price.
Ace investor Mukul Agrawal holds 1,400,000 equity shares equivalent to 1.5 percent in the company as of September 2024.
The foreign institutional investors of the company increased their stake by 3.37%, from 26.71% in Q1FY25 to 30.08% in Q2FY25. Additionally, 25.83% is owned by retail investors, 18.24% is held by domestic institutional investors, and 25.84% is owned by promoters.
Written by:- Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
